Kebir, Sied and Schaub, Christina and Junold, Nina and Hattingen, Elke and Schaefer, Niklas and Steinbach, Joachim P. and Weyerbrock, Astrid and Hau, Peter and Goldbrunner, Roland and Galldiks, Norbert and Weller, Johannes and Mack, Frederic and Tzaridis, Theophilos and Baehr, Oliver and Seidel, Clemens and Schlegel, Uwe and Schmidt-Graf, Friederike and Rohde, Veit and Borchers, Christian and Tabatabai, Ghazaleh and Haenel, Mathias and Sabel, Michael and Gerlach, Ruediger and Krex, Dietmar and Belka, Claus and Vatter, Hartmut and Proescholdt, Martin and Glas, Martin and Herrlinger, Ulrich (2019) Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. JOURNAL OF NEURO-ONCOLOGY, 144 (3). pp. 501-509. ISSN 0167-594X, 1573-7373
Full text not available from this repository. (Request a copy)Abstract
Purpose The phase II GLARIUS trial assigned patients with newly diagnosed, O-6-methylguanine-DNA methyltransferase promoter non-methylated glioblastoma to experimental bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ). To identify subpopulations with a particularly favorable course, we assessed the prognostic potential of magnetic resonance imaging (MRI) markers before treatment onset. Methods MRIs at baseline (before treatment onset) were analyzed for T1-hyperintense and diffusion-restricted lesions; as well as the presence of both hyperintense and diffusion-restricted (double positive) lesions. The MRI findings were correlated with overall and progression-free survival. Results MRI scans were evaluable in 71% of the GLARIUS modified intention-to-treat population (n = 121 of 170; 88 patients in the BEV/IRI arm, and 33 patients in the TMZ control arm). Diffusion-restricted and T1 hyperintense lesions were present in 60% and 65% of patients in BEV/IRI arm, while 57% and 63% were found in the TMZ arm, respectively. Double positive lesions were found in 37% of BEV/IRI patients and in 39% of TMZ patients. Neither the presence of T1-hyperintense, diffusion-restricted lesions, nor double positive lesions were associated with improved survival. Conclusions Baseline T1-hyperintense and diffusion-restricted lesions are not suitable to predict progression-free or overall survival of patients treated with bevacizumab/irinotecan or temozolomide.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PREDICTIVE IMAGING BIOMARKER; ADC HISTOGRAM ANALYSIS; CEREBRAL BLOOD-VOLUME; RECURRENT GLIOBLASTOMA; PLUS IRINOTECAN; TEMOZOLOMIDE; PROGRESSION; EFFICACY; Bevacizumab; Irinotecan; Newly diagnosed MGMT-non-methylated glioblastoma; MRI; Predictive and prognostic implications |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurochirurgie Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 30 Mar 2020 13:47 |
| Last Modified: | 30 Mar 2020 13:47 |
| URI: | https://pred.uni-regensburg.de/id/eprint/26311 |
Actions (login required)
 |
View Item |
